eli lilly retatrutide clinical trials stock jumps on Phase 3 weight loss results White House denies Trump is

Semaglutide GLP-1 is an FDA-approved medication that has shown significant benefits in weight reduction

Average body weight reductions ranged from approximately 15% to 21% depending on dose at 72 weeks - again from the studied FDA-approved formulation under controlled conditions

For researchers tracking this space, the key trials to watch in 2026 include the remaining TRIUMPH program readouts for retatrutide, the GLORY-OSA trial for mazdutide in obstructive sleep apnea, and the first Phase 1 data from several quadruple-agonist programs entering clinical development

K., GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data, Dec